Cyprus-based Barlenco Ltd., affiliated with the largest Ukrainian mining and metallurgical group Metinvest, in accordance with the law on joint stock companies has confirmed its intention to exercise the right to compulsory redemption of shares (squeeze-out) from minority shareholders of PrJSC Dniprovsky Coke Chemical Plant (formerly Evraz-Dniprodzerzhynsk Coke and Chemical Plant, Kamianske, formerly Dniprodzerzhynsk, Dnipropetrovsk region)
According to the official data of the plant in the information disclosure system of the National Securities and the Stock Market Commission, Dniprovsky Coke Chemical Plant received a notification from the shareholders on November 18 of this year.
As reported, PrJSC Dniprovsky Coke Chemical Plant received a notification from Metinvest B.V. on the achievement of a dominant controlling stake in the enterprise on October 21 of this year. Then it was clarified that the direct share of Metinvest B.V. increased from 73.37% (500.623 million shares) to 97.01%. At the same time, the aggregate ownership of shares in Dniprovsky Coke Chemical Plant by Metinvest (with the affiliated company Barlenco Ltd (Cyprus), which owns another 2.09% of the company’s shares) reached 99.1%. price of UAH 1.62 per ordinary share.
As reported, Metinvest B.V. in April 2019 announced a proposal to buy back shares from minority shareholders of Dniprovsky Coke Chemical Plant as part of the sell-out procedure (buyback at the request of the minority shareholder based on Articles 68 and 69 of the law on joint stock companies).Metinvest B.V. in mid-March 2020, announced the completion of the transaction to acquire a stake in PrJSC Dniprovsky Coke Chemical Plant and currently owns about 73% of the company’s shares. Back in 2014, Metinvest Group sent an application to the Antimonopoly Committee of Ukraine to acquire a controlling stake in Dniprovsky Coke Chemical Plant. About a year ago, the AMCU approved this deal subject to a number of restrictions. Prior to this, Metinvest received a number of permits from the antimonopoly authorities of other countries to acquire this enterprise.
The charter capital of the plant is UAH 170.584 million.
PJSC ArcelorMittal Kryvyi Rih (Dnipropetrovsk region) in January-October of this year reduced the output of general rolled products, according to recent data, by 3.8% compared to the same period last year, up to 3.69 million tonnes.
As the representative of the enterprise informed the Interfax-Ukraine agency, steel production during this period decreased by 16.6%, to 3.8 million tonnes, pig iron by 11.3%, to 4 million tonnes. At the same time, sinter production decreased by 11.5% to 7.36 million tonnes.
In October, 320,000 tonnes of rolled metal, 350,000 tonnes of steel, 380,000 tonnes of pig iron, 700,000 tonnes of sinter were produced.
As reported, ArcelorMittal Kryvyi Rih over 2019 increased the output of general rolled products by 11.2% compared to the previous year, to 4.665 million tonnes, steel by 11.8%, to 5.327 million tonnes, pig iron by 14.9%, to 5.310 million tonnes, sinter production increased by 14.3%, to 9.831 million tonnes.
ArcelorMittal Kryvyi Rih is the largest manufacturer of rolled steel in Ukraine. It specializes in production of long products, in particular, rebar and wire rod.
ArcelorMittal owns the largest mining and metallurgical plant in Ukraine ArcelorMittal Kryvyi Rih and a number of small companies, in particular, PJSC ArcelorMittal Beryslav.
FREE REGISTATION
DATE & TIME:
December 9, 13:00 – 14:30 GMT
TOPICS AND QUESTIONS TO BE DISCUSSED:
The growing share of VRE sources, such as solar and wind, calls for a more flexible energy system to accommodate intermittent energy generation efficiently and reliably. Battery storage systems are emerging as one of the potential solutions to increase system flexibility.
Both large-scale and small-scale battery storage deployment has been increasing rapidly across America, Europe & Asia-Pacific.
What are the opportunities for Emerging Markets?
AMONG CONFIRMED SPEAKERS:
– Patrick Clerens, Secretary-General, The European Association for Storage of Energy
– Peter Mockel, Principal Industry Specialist, IFC
– Luis Munuera, Smart Grids Technology Lead, International Energy Agency
– Emin Askerov, Director General, RENERA (Rosatom)
– Julian Jansen, Research Manager, Energy Storage, Clean Technology & Renewables, IHS Markit
You can learn more on the event’s official website: https://www.investinnet.com/energy-talks/ or contact the organisers: info@investinnet.com
Open4Business is an official information partner of the event.
FREE REGISTATION
DATE & TIME:
December 10, 09:30 – 11:00 GMT
TOPICS AND QUESTIONS TO BE DISCUSSED:
Green Hydrogen is having a moment around the world. Now new players are entering the market:
The Georgian government has recently asked the EBRD to explore the country’s potential for generating green hydrogen which could then be blended and transported to end-users through existing gas pipelines.
Ukraine has the potential for substantial hydrogen production – it is estimated that approximately 505,133 million m3 of green hydrogen could be produced in Ukraine annually. Various hydrogen-related projects are starting to be unveiled in the country.
AMONG CONFIRMED SPEAKERS:
– Aleksandr Riepkin, President, Ukrainian Hydrogen Council
– Daniel Potash, Chief of Party, USAID Energy Program
– David Managadze, Associate Director, Regional Head – Caucasus, Energy Eurasia, EBRD
– Jorgo Chatzimarkakis, Secretary-General, Hydrogen Europe
You can learn more on the event’s official website: https://www.investinnet.com/energy-talks/ or contact the organisers: info@investinnet.com
Open4Business is an official information partner of the event.
The biopharmaceutical company Biopharma (Kyiv) is limited in possibilities of increasing production of the Bioven medication (immunoglobulin) due to the lack of plasma donation culture in Ukraine and the lack of plasma, Oksana Plotnikova, director of strategic development at Biopharma, has said.
“We would like to expect an increase in Bioven production, which is why we are creating plasma centers to increase donor activity among the population. We have many blood donors, but the country does not have a culture of plasma donation for fractionation,” she said at a press conference on the completion of clinical trials of the Bioven drug in the complex therapy of patients with coronavirus disease (COVID-19) on Wednesday.
Plotnikova said that as the world completes clinical trials confirming the effectiveness of drugs based on blood plasma in treatment of COVID-19, the demand for such drugs, and, therefore, plasma will grow.
“We are on the verge of the fact that many countries – Canada, Europe – will restrict imports. There will be no imported drug in the country,” she said.
Plotnikova reported that “Ukrainian donors today do not donate the amount of plasma that could meet the needs of Ukraine.”
“Today, in order to provide Ukraine, we buy plasma from the United States, Slovakia. We cannot buy Indian or Vietnamese plasma, because we do not buy plasma that is not standardized under European standards,” she said.
Plotnikova said that Biopharma actively cooperates with communal blood centers, “so that communal stations develop, reconstruct and procure not only blood components for hospitals, but also plasma for fractionators to provide Ukraine with drugs.”
“The demand for intravenous infusion of immunoglobulin G, and subsequently convalescent plasma and hyperimmune immunoglobulin, is obvious. Today we see and understand that the real effectiveness of the drug makes it possible to save lives, which means that the need is growing,” she said.
Ratio of fertility and mortality by region as of Jan-Aug, 2020
SSC of Ukraine
